嘴细胞中的阿雷科林反映了阿雷卡坚果的剂量
Jennifer F Lai1, Ana Joy Mendez2, Xingnan Li1
1University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Drug testing and analysis
|April 7, 2024
概括
口腔细胞阿雷科林显示为阿雷卡坚果 (AN) 剂量的生物标志物具有前途,有助于AN停止研究. 这一发现支持使用阿雷科林水平来衡量AN消耗和戒烟有效性.
科学领域:
- 毒理学 毒理学 毒理学
- 生物标志物 生物标志物
- 公共卫生 公共卫生
背景情况:
- 阿雷卡坚果 (AN) 的使用是由于其致癌性质而引起的全球健康问题.
- 有效的AN戒断策略受到缺乏可靠的AN剂量生物标志物的阻碍.
- 阿雷科林是AN的主要化物,是停止生物标志物的潜在候选者.
研究的目的:
- 为了确定口腔细胞 (BCs) 中的阿雷科林水平,作为量化阿雷卡坚果 (AN) 剂量的可靠生物标志物.
- 调查自我报告的AN剂量 (平均AN负载,AANL) 和BC阿雷科林度之间的相关性.
- 根据AN消费模式 (Class 1和Class 2的者,有或没有石灰) 探索这种关联的潜在差异.
主要方法:
- 招募了103名阿拉卡坚果者,收集自我报告的AN消费数据 (AANL).
- 在口腔细胞 (BCs) 中测量阿雷科林度,使用液态染色体质谱法.
- 采用回归分析,将转化AANL与转化BC的阿雷科林水平相关联,分析子组.
主要成果:
- 在所有参与者 (r=0.40,p<0.01) 中,在AANL和BC阿雷科林水平之间发现了显著的正相关性.
- 这种关联在1类者 (r=0.51,p<0.01) 和那些与石灰一起食用AN的人中最强.
- 作为AN剂量的生物标志物,BC阿雷科林的可靠性被证明是可靠的,无论石灰含量如何,都有类似的关联,但类之间存在差异.
结论:
- 口腔细胞阿雷科林作为可靠的生物标志物用于估计阿雷卡坚果 (AN) 剂量.
- 这种生物标志物可以有助于评估AN戒烟干预措施的有效性.
- 这些发现支持在评估AN行为的基于人群的研究中使用BC阿雷科林测量.
更多相关视频
11:56A Rapid and Specific Microplate Assay for the Determination of Intra- and Extracellular Ascorbate in Cultured Cells
Published on: April 11, 2014
13.5K
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.6K
相关概念视频
01:03Dose-Response Relationship: Overview
3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K
01:23Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
01:18Drug Delivery: Enteral Route
428
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
428
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
953
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
953